Compounds > 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane

2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane and Substance-Withdrawal-Syndrome

2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane has been researched along with Substance-Withdrawal-Syndrome* in 1 studies

Trials

1 trial(s) available for 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane and Substance-Withdrawal-Syndrome

Article	Year
Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12 Between 4% and 14% of patients diagnosed with Parkinson's disease and entering clinical trials have normal presynaptic dopaminergic imaging. The effects of antiparkinsonian therapy have varied in these studies, and the consequences of stopping treatment are not reported. We present 11 patients who initially fulfilled diagnostic criteria and were treated for Parkinson's disease but in whom emerging diagnostic doubts led to antiparkinsonian therapy withdrawal, which was achieved without deterioration. Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials. Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Tomography, Emission-Computed, Single-Photon; Tropanes	2006

Article

Year

Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.

Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12

Between 4% and 14% of patients diagnosed with Parkinson's disease and entering clinical trials have normal presynaptic dopaminergic imaging. The effects of antiparkinsonian therapy have varied in these studies, and the consequences of stopping treatment are not reported. We present 11 patients who initially fulfilled diagnostic criteria and were treated for Parkinson's disease but in whom emerging diagnostic doubts led to antiparkinsonian therapy withdrawal, which was achieved without deterioration. Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials.

Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Tomography, Emission-Computed, Single-Photon; Tropanes

2006